ConductScience.org, home

Paper29720221

Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.

Chen YL and 9 others. Arthritis Res Ther, 2018. Cited by 10 papers, by iCite.

Cite this record

ConductScience Library. Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study. Papers, record 29720221. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29720221

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study.
PubMed
Journal
Arthritis Res Ther
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.45
iCite
Revised in PubMed
2019-12-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen YLYu-Lan
2Lin JZJian-Zi
3Mo YQYing-Qian
4Ma JDJian-Da
5Li QHQian-Hua
6Wang XYXiao-Ying
7Yang ZHZe-Hong
8Yan TTao
9Zheng DHDong-Hui
10Dai LLie

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antirheumatic AgentsMajor topic
Arthritis, RheumatoidMajor topic
Hepatitis B, ChronicMajor topic
Adult
Antiviral Agents
Case-Control Studies
Female
Guanine
Hepatitis B virus
Humans
Logistic Models
Male
Middle Aged
Outcome Assessment, Health Care
Remission Induction
Retrospective Studies
Severity of Illness Index
Tenofovir

Source PubMed

Download CSV of topics

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1206992412010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Ann Rheum Dis2010https://conductscience.org/library/papers/20699241PubMed
211296944Rheumatoid arthritis and hepatitis B virus: evaluating the pathogenic link.J Rheumatol2001https://conductscience.org/library/papers/11296944PubMed
320870315[Hepatitis B virus, extrahepatic immunologic manifestations and risk of viral reactivation].Rev Med Interne2011https://conductscience.org/library/papers/20870315PubMed
425447852American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology2015https://conductscience.org/library/papers/25447852PubMed
522565315Management of rheumatic disease with comorbid HBV or HCV infection.Nat Rev Rheumatol2012https://conductscience.org/library/papers/22565315PubMed
622473918Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.Arthritis Care Res (Hoboken)2012https://conductscience.org/library/papers/22473918PubMed
77921766Acute sero-positive rheumatoid arthritis occurring after hepatitis vaccination.Br J Rheumatol1994https://conductscience.org/library/papers/7921766PubMed
815189743Leflunomide in the treatment of rheumatoid arthritis.Clin Ther2004https://conductscience.org/library/papers/15189743PubMed
925147433Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis.Mediators Inflamm2014https://conductscience.org/library/papers/25147433PubMed
1018512708American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum2008https://conductscience.org/library/papers/18512708PubMed
1120444750EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.Ann Rheum Dis2010https://conductscience.org/library/papers/20444750PubMed
1215784044Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease.Am J Gastroenterol2005https://conductscience.org/library/papers/15784044PubMed
1316539831Rapidly destructive knee arthropathy associated with hepatitis B.Clin Exp Rheumatol2006https://conductscience.org/library/papers/16539831PubMed
142290175Reactive arthritis after hepatitis B vaccination.J Rheumatol1990https://conductscience.org/library/papers/2290175PubMed
159733447The development of rheumatoid arthritis after recombinant hepatitis B vaccination.J Rheumatol1998https://conductscience.org/library/papers/9733447PubMed
1625532827
Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
BMC Musculoskelet Disord2014https://conductscience.org/library/papers/25532827PubMed
1715763339Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3.J Hepatol2005https://conductscience.org/library/papers/15763339PubMed
1824161836EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.Ann Rheum Dis2014https://conductscience.org/library/papers/24161836PubMed
19224739172012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken)2012https://conductscience.org/library/papers/22473917PubMed
2022021897Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.Ann Rheum Dis2012https://conductscience.org/library/papers/22021897PubMed

See all 38 referencesDownload CSV of references

Cited by9

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
42027193Serological evidence linking viral infections to incident risk of hip and knee osteoarthritis.Bone Joint Res2026https://conductscience.org/library/papers/42027193PubMed
41782135Association between periodontitis and hepatocellular carcinoma across different tumor stages.BMC Oral Health2026https://conductscience.org/library/papers/41782135PubMed
40260684
Indications and contraindications to platelet-rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injections).
Knee Surg Sports Traumatol Arthrosc2025https://conductscience.org/library/papers/40260684PubMed
39682184Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas.Cancers (Basel)2024https://conductscience.org/library/papers/39682184PubMed
36188738Hepatitis B virus infection reactivation in patients under immunosuppressive therapies: Pathogenesis, screening, prevention and treatment.World J Virol2022https://conductscience.org/library/papers/36188738PubMed
35244954Periodontitis, chronic liver diseases, and the emerging oral-gut-liver axis.Periodontol 20002022https://conductscience.org/library/papers/35244954PubMed
34200522Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.J Clin Med2021https://conductscience.org/library/papers/34200522PubMed
33294150Neglected extra-articular manifestations in rheumatoid arthritis patients with normal body mass index: reduced skeletal muscle overlapping overfat.Ther Adv Chronic Dis2020https://conductscience.org/library/papers/33294150PubMed
32922525Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis.Ther Adv Musculoskelet Dis2020https://conductscience.org/library/papers/32922525PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
MMP34314PubTator's text mininghttps://conductscience.org/library/genes/4314NCBI Gene
PLGLA285189PubTator's text mininghttps://conductscience.org/library/genes/285189NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29720221

GET https://conductscience.org/api/papers/v1/29720221/references?page=2